A meta-analysis of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues with add-back therapy

• Published in: Chung-hua fu chʿan kʿo tsa chih Vol. 48; no. 5; p. 338
• Main Authors: Niu, Zi-ru, Yue, Xiao-jing, Kong, Qun-yu, Wang, Yuan-fen, Yao, Yuan-qing
• Format: Journal Article
• Language: Chinese
• Published: China 01.05.2013
• Subjects: Bone Density - drug effects; Drug Administration Schedule; Drug Therapy, Combination; Endometriosis - drug therapy; Estrogen Antagonists - administration & dosage; Estrogen Antagonists - therapeutic use; Estrogens - administration & dosage; Estrogens - therapeutic use; Female; Gonadotropin-Releasing Hormone - administration & dosage; Gonadotropin-Releasing Hormone - analogs & derivatives; Humans; Leuprolide - administration & dosage; Leuprolide - therapeutic use; Lumbar Vertebrae; Pain Measurement; Pelvic Pain - drug therapy; Randomized Controlled Trials as Topic
• ISSN: 0529-567X

To evaluate the role and efficacy of preventing bone mineral loss in patients with endometriosis treated by gonadotrophin-releasing hormone analogues (GnRH-a) combined with add-back therapy. Prospective, randomized controlled studies of the use of GnRHa with add-back therapy in treatment of endometriosis were enrolled in this study from Medline, Embase, Cochrane library, China National Knowledge Internet (CNKI), Chinese Biological Medicine Disk (CBM) and Data Base of Wanfang.After quality assessment and data extraction, meta-analysis were conducted in the change of BMD, reproductive hormone (E2) and visual pain score(VAS) by Stata 11.0 software. A total of 785 patients from 13 randomized controlled trail (RCT) studies enrolled in this study after exclude no following up, poor quality and repeat published studies.377 patients were in group of GnRH-a with add-back treatment and 408 patients were in group of GnRna alone.The findinds were showed in meta-analysis: (1) there was a significant difference in percenta